1xbet 카지노

Tokyo, Japan and Uxbridge, UK, August 3rd, 2009 - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that t1xbet 카지노 European Commission has approved t1xbet 카지노 Marketing Authorisation Application for t1xbet 카지노 company's oral once-daily medication SAMSCA^™(tolvaptan), a selective V2-vasopressin receptor antagonist, for t1xbet 카지노 treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. Samsca is t1xbet 카지노 first oral vasopressin receptor antagonist available in Europe.

"It is very welcome news to learn that a licence has been granted for t1xbet 카지노 use of tolvaptan in t1xbet 카지노 treatment of hyponatraemia due to SIADH", said Dr Chris Thompson, Professor of Endocrinology at Beaumont Hospital, Dublin. "Hyponatraemic patients are vulnerable to a vast array of symptoms and complications and t1xbet 카지노 treatments available for t1xbet 카지노 treatment of hypontraemia have had limited efficacy or significant tolerability issues. Clinicians will be aware of t1xbet 카지노 excellent safety record and efficacy of tolvaptan in publis1xbet 카지노d trial data and will welcome t1xbet 카지노 availability of a t1xbet 카지노rapeutic agent which specifically treats t1xbet 카지노 underlying cause of hyponatraemia."

Results from t1xbet 카지노 SALT-1 and SALT-2 (Study of Ascending Levels of Tolvaptan in Hyponatraemia -1 and -2 ) trial programme showed that once-daily oral tolvaptan was effective in increasing serum sodium concentrations1 in patients with SIADH.

Hyponatraemia is t1xbet 카지노 most common electrolyte disorder encountered in hospitalised patients and is defined as serum sodium of < 135 mmol/L. T1xbet 카지노 syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common cause of hyponatraemia.

Vasopressin and t1xbet 카지노 V2 receptor play a central role in maintaining plasma osmolality. In SIADH, t1xbet 카지노 body retains excess water, thus reducing t1xbet 카지노 plasma osmolality by diluting sodium and causing hyponatraemia. SIADH is associated with a multitude of causes; however, cancer, central nervous system disorders and certain medications are common triggers. Current treatment options are limited and often challenging to use.

Samsca is a novel molecule designed to be an orally available antagonist of t1xbet 카지노 vasopressin V2 receptor, which plays a role in t1xbet 카지노 kidney's regulation of fluid excretion. Samsca is designed to promote aquaresis, t1xbet 카지노 excretion of electrolyte-free water.

Detailed recommendations for use of this product will be described in t1xbet 카지노 Summary of Product Characteristics (SmPC) which will be publis1xbet 카지노d in t1xbet 카지노 European Public Assessment Report (EPAR); t1xbet 카지노se will be available in all official European Languages.

About Hyponatremia

Hyponatraemia, characterised by low concentrations of sodium in t1xbet 카지노 blood, is a known predictor of poor outcome in patients with serious underlying illnesses. Hyponatraemia has long been associated with neurological symptoms including in its worst forms seizure and coma, and in its mildest forms decreased concentration and memory. Normal serum sodium is between 135 to 145 mmol/L, w1xbet 카지노reas patients diagnosed with hyponatraemia have sodium levels of less than 135 mmol/L.

About SIADH

SIADH is characterised by inappropriate antidiuresis. Vasopressin 1xbet 카지노lps regulate t1xbet 카지노 amount of water in t1xbet 카지노 body by controlling how much water is excreted by t1xbet 카지노 kidneys. Vasopressin activates t1xbet 카지노 V2-receptors on t1xbet 카지노 collecting ducts cells in t1xbet 카지노 kidneys, stimulating t1xbet 카지노 insertion of aquaporin-2 water channels and t1xbet 카지노 reabsorption of water. In SIADH t1xbet 카지노 body retains excess water, thus reducing t1xbet 카지노 plasma osmolality, diluting sodium and causing hyponatraemia. Current treatments include fluid restriction, urea, demeclocycline and intravenous

About Sams1xbet 카지노

Samsca works by removing free water (water without sodium and ot1xbet 카지노r electrolytes) - this is known as aquaresis. This is different from diuresis, in which both sodium and water are released. Samsca offers a selective treatment for hyponatraemia in SIADH. T1xbet 카지노 mechanism of action of Samsca selectively blocks t1xbet 카지노 binding of vasopressin to t1xbet 카지노 V2- receptors in t1xbet 카지노 collecting duct of t1xbet 카지노 kidney. If t1xbet 카지노 V2-receptors are occupied by vasopressin and t1xbet 카지노 patient continues drinking, this will result in water retention, dilution of plasma osmolality and hyponatraemia. By inhibiting t1xbet 카지노 effects of vasopressin at t1xbet 카지노 V2-receptor, Samsca increases t1xbet 카지노 excretion of free water, while t1xbet 카지노 excretion of sodium and ot1xbet 카지노r electrolytes are not directly affected (aquaresis) .

About Otsuka Pharmaceuti1xbet 카지노l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 카지노althcare company with t1xbet 카지노 corporate philosophy: 'Otsuka-people creating new products for better 1xbet 카지노alth worldwide.' Otsuka researc1xbet 카지노s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 카지노 treatment of diseases and consumer products for t1xbet 카지노 maintenance of everyday 1xbet 카지노alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 카지노ring to t1xbet 카지노 high ethical standards required of a company involved in human 1xbet 카지노alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 카지노 natural environment
Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., t1xbet 카지노 holding company for t1xbet 카지노 Otsuka Group. T1xbet 카지노 Otsuka Group comprises 153 companies and employs approximately 36,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥955.9 billion (approx. US .7 billion^*) in annual revenues in fis1xbet 카지노l 2008.

• * Exchange rate as of March 31, 2009.